Stocks including Sprix, Kissei Pharmaceutical and Pigeon moved sharply as stocks attracted buying on raised earnings forecasts for the fiscal year ending September 2027 and announcements of major acquisitions and partnerships.
Sprix continued to be viewed favorably after presenting consolidated forecasts for the fiscal year ending September 2027 of ¥42.0 billion in revenue, up 9.8% year on year, and ¥3.8 billion in operating profit, up 27.0%, and setting its full-year dividend forecast at ¥44.
Kissei Pharmaceutical attracted buying after US-based CG Oncology announced that its bladder cancer drug candidate had produced statistically significant and clinically meaningful results in a Phase 3 trial, and because the company entered into a licensing agreement in 2020 to acquire exclusive development and marketing rights for the drug in 20 Asian countries.
Pigeon announced that it would make US-based Illyo Brands a subsidiary on 8 January next year, local time, for an estimated purchase price of approximately ¥61.0 billion. The move raised expectations for an expanded sales channel in the United States, prompting a response in the share price.
Iore was viewed favorably after revising its earnings forecast for the fiscal year ending March 2027 after the close on the 16th, raising its net income forecast substantially from the previous ¥1.27 billion to ¥2.234 billion.